Bispecific antibodies (bsAbs) are a promising novel treatment approach for relapsed/refractory multiple myeloma (MM), but carry the risk of infectious adverse events. An expert infectious disease faculty will co-present this on-demand video with an MM expert to hone skills in identifying risk factors and recognizing the signs and symptoms associated with infectious adverse events of bsAb therapy. Don’t miss this opportunity to hear best practices for multidisciplinary co-management strategies for infectious complications of bsAbs in patients with MM to ensure your readiness to provide exceptional care for this growing population of patients.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/transforming-mm-management-strategies-infectious-disease-teams-using
- Start Date: 2024-08-21 05:00:00
- End Date: 2024-08-21 05:00:00
- Credit Details: IPCE Credits: 0.25 hours
AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: Source: Janssen (Any division) - Amount: 12500.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest